Close menu

September 27th, 2023 | 07:10 CEST

Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

  • Biotechnology
  • Pharma
Photo credits:

High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!

time to read: 3 minutes | Author: Nico Popp

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Schott Pharma: Big returns with small vials?

    On Tuesday afternoon, the banks involved in the IPO of Schott Pharma announced that they had narrowed the price range to EUR 26.50 to 27. This means that the proceeds will likely be in the upper-middle range of the original spread. Schott Pharma is thus valued at around EUR 4 billion. The Company is part of glass giant Schott AG, which will remain the majority shareholder after the IPO with around 77% of the shares. Qatar Holding, a significant anchor shareholder, is also involved in the IPO. The funds raised will flow to the parent company. Schott Pharma says it does not necessarily need capital but wants to accelerate its growth.

    The Company, which produces glass ampoules, vials and syringes, has scored with solid figures in the past - among other things, its operating profit margin of 28% is impressive. The recently emerging trend for mRNA therapeutics and the weight loss injection Wegovy® is particularly promising for growth prospects. The current situation with BioNTech's vaccines also highlights the importance of packaging, as their vaccines are delivered in multiple-dose containers. While this approach made sense for vaccination centers in 2021, in 2023, valuable vaccines may be discarded due to insufficient recipients for these "bulk packages." Competitors, such as Moderna, have long been supplying single doses; however, there are no supply agreements with Germany. Schott Pharma's stock scores with solid figures and robust business. However, the stock does not yet have a track record. Investors may not find compelling reasons to invest in the current market environment.

    BioNTech: How low can we go?

    The same applies to the German mRNA pioneer BioNTech. The share is stuck in a long-term downtrend. Although the Coronavirus is still generating sales, the willingness to vaccinate is dropping significantly. However, investors should keep an eye on BioNTech's numerous promising projects. With the pandemic billions, BioNTech can research in peace at its own pace - the Mainz-based biotech should never be written off, not only because of its history. However, there is also no immediate urgency to take action.

    Cardiol Therapeutics: Progress in Studies, Capital - Ingredients for a Breakthrough?

    The situation is somewhat different for the Nasdaq-listed biotech company Cardiol Therapeutics. The Company develops active substances against rare inflammatory heart diseases, such as myocarditis. A multicenter, international, double-blind, randomized, placebo-controlled Phase II ARCHER study is currently underway to evaluate the safety and tolerability of CardiolRx™ in patients with acute myocarditis. In rare diseases, recruiting enough patients for studies is often challenging. However, Cardiol Therapeutics recently announced that it will be able to complete enrollment of patients in the third quarter of 2024, six months earlier than expected.

    Dr. Andrew Hamer, Chief Medical Officer at Cardiol Therapeutics, commented: "The data generated from patients enrolled in the ARCHER trial will provide important information supporting the use of CardiolRx™ as a novel small molecule therapeutic in this severely debilitating, rare disease. This condition is considered an important trigger for acute and fulminant heart failure and a leading cause of sudden cardiac death in people under 35 years of age, and for which there are no approved therapies." Thanks to a significant capital raise conducted by the Company in 2021, Cardiol Therapeutics still has sufficient funds to continue its trials. The stock has doubled since April but has further long-term catch-up potential from a chart perspective. If the Company delivers positive study results, the penny stock could rebound.

    Cardiol Therapeutics operates in an exciting medical field, is solidly financed and could benefit from extended patent protection in the event of market approval, as myocarditis is considered a rare disease. While Schott Pharma, a newcomer to the stock market, does not yet have a track record, and BioNTech is in a downtrend, Cardiol Therapeutics has a comeback on the horizon. However, given the ongoing clinical trials the stock must be considered speculative.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

    TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

    • Biotechnology
    • Pharma
    • Innovations
    • Cancer

    There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?


    Commented by Juliane Zielonka on April 22nd, 2024 | 07:00 CEST

    Cardiol Therapeutics, Bayer AG, Fresenius - Who will be the trendsetter in tomorrow's healthcare market?

    • Biotechnology
    • Pharma
    • Healthcare

    The healthcare sector is a lucrative segment for risk-conscious investors. The global healthcare services market size is expected to achieve a compound annual growth rate (CAGR) of 8.96% by 2028. Understanding local healthcare needs is the basis for the growth of companies such as Cardiol Therapeutics, Bayer and Fresenius. Cardiol Therapeutics is a promising life sciences company researching several heart diseases with a focus on heart health and developing suitable medication. A disease such as heart failure (HF), for example, affects 26 million people worldwide and offers high scaling potential for the Canadian researchers and developers at Cardiol. Bayer also recognizes the market potential and would like to supply this target group with a gene therapy via Fast Track. Fresenius is familiar with market conditions due to expiring patent protection and is launching a lucrative biosimilar in the US. Which of these three companies will set the trend in the healthcare market of the future?


    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.